Abstract

SAROGLITAZAR: NEW ANTIDIABETIC ON THE HORIZON

Dr. Pradeep Kawatra and Dr. Pallavi Kawatra

ABSTRACT

Diabetic dyslipidemia is one of the foremost risk factors for development of cardiovascular diseases. Most of the patients, suffering from this condition, are candidates for treatment with drugs such as statins or fibrates in order to achieve the required therapeutic lipid levels. The Peroxisome proliferator-activated receptors (PPAR) family of nuclear receptors for long has been targeted by the physicians through drugs such as thiazolidinediones to improve the insulin resistance by their action on PPAR γ. However, a new approach intends to target both PPAR α and γ receptor subtypes simultaneously to improve the lipid as well as the glucose levels respectively in patients with diabetic dyslipidemia. Saroglitazar, the first of its kind to enter the Indian market is a dual PPAR agonist. It can aid in not only providing glycemic control but also in achieving the adequate plasma lipid levels, thereby decreasing the need of additional medications in such patients. This review highlights the emergence of glitazar group of drugs and the possibility of Saroglitazar becoming the drug of this decade.

Keywords: Saroglitazar, Diabetic dyslipidemia, PPAR, thiazolidinediones.